Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

NEXT STORY
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
PREV STORY
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SEngine Precision Medicine to Present Data Related to the Predictive Value of PARIS® Test, an Organoid-based Drug Response Assay, for Cholangiocarcinoma Patients at 2020 AACR Virtual Meeting Session II

author_avatar
NASDAQ Market News

Global Defibrillator Market to Expand at 5.3% CAGR and Reach USD 14,806.4 Million by 2026

author_avatar
NASDAQ Market News

Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

SAN FRANCISCO and TEL AVIV, Israel, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, ...

author_avatar
NASDAQ Market News